Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension

References

• AraiHHoriSAramoriI1990Cloning and expression of a cDNA encoding an endothelin receptorNature34873022175396
   PubMed Web of Science ®Google Scholar
• BarstRJIvyDDingemanseJ2003Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertensionClin Pharmacol Ther733728212709727
   PubMed Web of Science ®Google Scholar
• BarstRJLanglebenDBadeschD2006Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.[see comment]J Am Coll Cardiol4720495616697324
   PubMed Web of Science ®Google Scholar
• BarstRJLanglebenDFrostA2000Sitaxsentan therapy for pulmonary arterial hypertensionAm J Resp Crit Care Med169441714630619
   PubMedGoogle Scholar
• BarstRJRichSWidlitzA2002Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot studyChest1211860812065350
   PubMed Web of Science ®Google Scholar
• BattistiniBBerthiaumeNKellandNF2006Profile of past and current clinical trials involving endothelin receptor antagonists: the novel “sentan” class of drugExp Biol Med (Maywood)2316539516740981
   PubMed Web of Science ®Google Scholar
• BenzaRLFrostAGirgisRE2006Chronic treatment of pulmonary arterial hypertension with sitaxsentan and bosentan [abstract]Proc Am Thorac Soc3A729
   Google Scholar
• BenzaRLMehtaSKeoghA2007Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentanJ Heart Lung Transplant2663917234519
   PubMed Web of Science ®Google Scholar
• BlackSMMata-GreenwoodEDettmanRW2003Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flowCirculation10816465412963646
   PubMed Web of Science ®Google Scholar
• BondermanDNowotnyRSkoro-SajerN2005Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertensionChest128259960316236930
   PubMed Web of Science ®Google Scholar
• ChannickRNSimonneauGSitbonO2001Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled studyLancet35811192311597664
   PubMed Web of Science ®Google Scholar
• DavieNHaleenSJUptonPD2002aET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cellsAm J Respir Crit Care Med16539840511818328
   PubMed Web of Science ®Google Scholar
• DavieNHaleenSJUptonPD2002bET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cellsAm J Resp Crit Care Med16539840511818328
   PubMed Web of Science ®Google Scholar
• de NucciGThomasRD’Orleans-JusteP1988Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factorProc Natl Acad Sci USA8597978003059352
   PubMed Web of Science ®Google Scholar
• DingemanseJBodinFWeidekammE2002aInfluence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonistJ Clin Pharmacol42283911865964
   PubMed Web of Science ®Google Scholar
• DingemanseJBodinFWeidekammE2002bInfluence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonistJ Clin Pharmacol42283911865964
   PubMed Web of Science ®Google Scholar
• DupuisJGoreskyCAFournierA1996aPulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptorsJ Appl Physiol81151058904561
   PubMed Web of Science ®Google Scholar
• DupuisJStewartDJCernacekP1996bHuman pulmonary circulation is an important site for both clearance and production of endothelin-1Circulation941578848840847
   PubMed Web of Science ®Google Scholar
• EvansAMCobbanHJNixonGF1999ET(A) receptors are the primary mediators of myofilament calcium sensitization induced by ET-1 in rat pulmonary artery smooth muscle: a tyrosine kinase independent pathwayBr J Pharmacol1271536010369468
   PubMed Web of Science ®Google Scholar
• GalieNBadeschDOudizR2005Ambrisentan therapy for pulmonary arterial hypertensionJ Am Coll Cardiol465293516053970
   PubMed Web of Science ®Google Scholar
• GalieNBeghettiMGatzoulisMA2006Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled studyCirculation114485416801459
   PubMed Web of Science ®Google Scholar
• GalieNHinderliterALTorbickiA2003Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertensionJ Am Coll Cardiol411380612706935
   PubMed Web of Science ®Google Scholar
• GiaidAYanagisawaMLanglebenD1993Expression of endothelin-1 in the lungs of patients with pulmonary hypertensionN Engl J Med328173298497283
   PubMed Web of Science ®Google Scholar
• GirgisREFrostAEHillNS2007Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue diseaseAnn Rheum Dis6614677217472992
   PubMed Web of Science ®Google Scholar
• HoeperMMKrammTWilkensH2005Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertensionChest12823636716236895
   PubMed Web of Science ®Google Scholar
• HoeperMMLeuchteHHalankM2006Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertensionEur Respir J286919417012628
   PubMed Web of Science ®Google Scholar
• HoeperMMTahaNBekjarovaA2003Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoidsEur Respir J22330412952269
   PubMed Web of Science ®Google Scholar
• HumbertMBarstRJRobbinsIM2004Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2Eur Respir J24353915358690
   PubMed Web of Science ®Google Scholar
• HumbertMMorrellNWArcherSL2004Cellular and molecular pathobiology of pulmonary arterial hypertensionJ Am Coll Cardiol4313S24S15194174
   PubMed Web of Science ®Google Scholar
• HumbertMSegalESKielyDG2007Results of European postmarketing surveillance of bosentan in pulmonary hypertensionEur Respir J303384417504794
   PubMed Web of Science ®Google Scholar
• IvyDDDoranAClaussenL2004Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentanAm J Cardiol93943615050507
   PubMed Web of Science ®Google Scholar
• JankovRPKantoresCBelcastroR2006Endothelin-1 inhibits apoptosis of pulmonary arterial smooth muscle in the neonatal ratPediatr Res602455116857764
   PubMed Web of Science ®Google Scholar
• JasminJFLucasMCernacekP2001Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertensionCirculation103314811208695
   PubMed Web of Science ®Google Scholar
• KimNHChannickRNRubinLJ2003Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertensionChest1241612514555600
   PubMed Web of Science ®Google Scholar
• LanglebenDDupuisJLanglebenI2006Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertensionChest1296899516537869
   PubMed Web of Science ®Google Scholar
• LanglebenDHirschAMShalitE2004Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin. A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up studyChest12613778115486408
   PubMed Web of Science ®Google Scholar
• McCullochKMDochertyCCMorecroftI1996EndothelinB receptor-mediated contraction in human pulmonary resistance arteriesBr J Pharmacol1191125308937714
   PubMed Web of Science ®Google Scholar
• McLaughlinVVOudizRJFrostA2006Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertensionAm J Respir Crit Care Med17412576316946127
   PubMed Web of Science ®Google Scholar
• McLaughlinVVSitbonOBadeschDB2005Survival with first-line bosentan in patients with primary pulmonary hypertension. [erratum Eur Respir J, 2005 25:942]Eur Respir J25244915684287
   PubMed Web of Science ®Google Scholar
• MathaiSCGirgisREFisherMR2007Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertensionEur Respir J294697517079256
   PubMed Web of Science ®Google Scholar
• MichelakisED2006Spatio-temporal diversity of apoptosis within the vascular wall in pulmonary arterial hypertension: heterogeneous BMP signaling may have therapeutic implicationsCirc Res98725
   Web of Science ®Google Scholar
• MurpheyLHoodE2003Bosentan and warfarin interactionAnn Pharmacother3710283112841813
   PubMed Web of Science ®Google Scholar
• OlschewskiHGalieNKramerM2006Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: results of the ARIES-2 study [abstract]Proc Am Thorac Soc3A278
   Google Scholar
• OudizRTorresFFrostA2006ARIES-1: A placebo controlled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertensionChest130121S
   Web of Science ®Google Scholar
• OudizRJBarstRJHansenJE2006Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertensionAm J Cardiol97123616377296
   PubMed Web of Science ®Google Scholar
• PaulGAGibbsJSBoobisAR2005Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertensionBr J Clin Pharmacol601071215963102
   PubMed Web of Science ®Google Scholar
• PulidoTKurzynaMSouzaR2006Sitaxsentan 100 mg proves more effective than sitaxsentan 50 mg patients with pulmonary arterial hypertension [abstract]Proc Am Thorac Soc3A417
   Google Scholar
• RubinJLSimonneauGHoeperMM2007Bosentan improves hemodynamics in patients receiving backgroundsildenafil treatment: results from EARLY, a randomized, double-blind, placebo-controlled study in patients with mildly symptomatic pulmonary arterial hypertension [abstract]Chest132487S
   Web of Science ®Google Scholar
• RubinLJBadeschDBBarstRJ2002Bosentan therapy for pulmonary arterial hypertension. [erratum N Engl J Med, 2002 346:1258]N Engl J Med34689690311907289
   PubMed Web of Science ®Google Scholar
• SakuraiTYanagisawaMTakuwaY1990Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptorNature34873252175397
   PubMed Web of Science ®Google Scholar
• SatoKOkaMHasunumaK1995Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungsAm J Physiol269L6686727491987
   PubMedGoogle Scholar
• ShichiriMKatoHMarumoF1997Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cellsHypertension3011982039369276
   PubMed Web of Science ®Google Scholar
• SitbonOBadeschDBChannickRN2003Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up studyChest1242475412853530
   PubMed Web of Science ®Google Scholar
• SitbonOGressinVSpeichR2004Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertensionAm J Respir Crit Care Med1701212715317666
   PubMed Web of Science ®Google Scholar
• SitbonOMcLaughlinVVBadeschDB2005Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenolThorax6010253016055621
   PubMed Web of Science ®Google Scholar
• SpenceSAndersonCCukierskiM1999Teratogenic effects of the endothelin receptor antagonist L-753, 037 in the rat. [erratum Reprod Toxicol, 1999 13:237]Reprod Toxicol13152910080296
   PubMed Web of Science ®Google Scholar
• SteinerMKPrestonIRKlingerJR2006Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot studyChest13014718017099026
   PubMed Web of Science ®Google Scholar
• SulemanNFrostAE2004Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertensionChest1268081515364760
   PubMed Web of Science ®Google Scholar
• TreiberASchneiterRHauslerS2007Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafilDrug Metab Dispos351400717496208
   PubMed Web of Science ®Google Scholar
• van GiersbergenPLHalabiADingemanseJ2002aSingle- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazoleBr J Clin Pharmacol535899512047483
   PubMed Web of Science ®Google Scholar
• van GiersbergenPLTreiberAClozelM2002bIn vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburideClin Pharmacol Ther712536211956508
   PubMed Web of Science ®Google Scholar
• VoelkelNFCoolCLeeSD1998Primary pulmonary hypertension between inflammation and cancerChest114225S30S9741573
   PubMed Web of Science ®Google Scholar
• WeberCSchmittRBirnboeckH1996aPharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjectsClin Pharmacol Ther60124378823230
   PubMed Web of Science ®Google Scholar
• WeberCSchmittRBirnboeckH1996bPharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjectsClin Pharmacol Ther60124378823230
   PubMed Web of Science ®Google Scholar
• WidlitzACBarstRJHornEM2005Sitaxsentan: a novel endothelin. A receptor antagonist for pulmonary arterial hypertensionExpert Rev Cardiovasc Ther39859116292989
   PubMedGoogle Scholar
• WilliamsonDJWallmanLLJonesR2000Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertensionCirculation102411810908213
   PubMed Web of Science ®Google Scholar
• WuCDeckerERBlokN2004aDiscovery, modeling, and human pharmacokinetics of N-(2-acetyl–4, 6-dimethylphenyl)-3-(3, 4-dimethylisoxazol–5-ylsulfamoyl) thio phene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonistJ Med Chem4719698615055997
   PubMed Web of Science ®Google Scholar
• WuCDeckerERBlokN2004bDiscovery, modeling, and human pharmacokinetics of N-(2-acetyl-4, 6-dimethylphenyl)-3-(3, 4-dimethylisoxazol–5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonistJ Med Chem4719698615055997
   PubMed Web of Science ®Google Scholar